X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1596) 1596
Publication (106) 106
Patent (49) 49
Book Review (20) 20
Book Chapter (12) 12
Book / eBook (4) 4
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (557) 557
gastroenterology & hepatology (513) 513
index medicus (359) 359
gastroenterology and hepatology (336) 336
female (329) 329
male (324) 324
adult (323) 323
middle aged (259) 259
ulcerative colitis (224) 224
inflammatory-bowel-disease (220) 220
crohn's disease (212) 212
infliximab (202) 202
treatment outcome (183) 183
crohn disease - drug therapy (179) 179
inflammatory bowel disease (160) 160
crohns-disease (147) 147
aged (146) 146
therapy (133) 133
adolescent (120) 120
ulcerative-colitis (120) 120
colitis, ulcerative - drug therapy (117) 117
severity of illness index (113) 113
abridged index medicus (109) 109
antibodies, monoclonal - therapeutic use (100) 100
clinical trials (96) 96
double-blind method (96) 96
remission induction (92) 92
adalimumab (88) 88
care and treatment (82) 82
maintenance therapy (81) 81
remission (80) 80
young adult (80) 80
inflammatory bowel diseases (76) 76
double-blind (74) 74
immunosuppressive agents - therapeutic use (74) 74
tumor necrosis factor-alpha - antagonists & inhibitors (71) 71
gastrointestinal agents - therapeutic use (68) 68
efficacy (67) 67
certolizumab pegol (64) 64
risk factors (63) 63
aged, 80 and over (62) 62
analysis (59) 59
gastroenterology (58) 58
anti-inflammatory agents - therapeutic use (56) 56
inflammatory bowel diseases - drug therapy (56) 56
crohn disease - diagnosis (54) 54
retrospective studies (53) 53
pharmacology & pharmacy (50) 50
azathioprine (49) 49
gastrointestinal diseases (49) 49
medicine, general & internal (49) 49
antibodies, monoclonal, humanized (48) 48
follow-up studies (48) 48
management (48) 48
surgery (48) 48
antibodies, monoclonal - adverse effects (46) 46
dose-response relationship, drug (46) 46
human necessities (46) 46
hygiene (46) 46
medical or veterinary science (46) 46
c-reactive protein (45) 45
crohn disease - pathology (45) 45
placebo-controlled trial (45) 45
prognosis (45) 45
risk (45) 45
article (44) 44
trial (44) 44
drug therapy (43) 43
safety (43) 43
diagnosis (42) 42
drug therapy, combination (42) 42
crohns disease (40) 40
ibd (40) 40
randomized controlled trials as topic (40) 40
time factors (40) 40
endoscopy (39) 39
medical research (39) 39
prevalence (39) 39
rheumatoid-arthritis (39) 39
colitis, ulcerative - pathology (38) 38
medical colleges (38) 38
anti-inflammatory agents, non-steroidal - therapeutic use (37) 37
crohn disease - complications (37) 37
induction (37) 37
monoclonal antibodies (37) 37
patients (37) 37
antibodies, monoclonal - administration & dosage (36) 36
colonoscopy (35) 35
drug administration schedule (35) 35
inflammatory bowel-disease (35) 35
colitis (34) 34
crohn disease - therapy (34) 34
gastrointestinal agents - adverse effects (34) 34
maintenance (34) 34
6-mercaptopurine (33) 33
antibodies, monoclonal, humanized - therapeutic use (33) 33
cohort studies (33) 33
pharmacokinetics (33) 33
quality-of-life (33) 33
administration, oral (32) 32
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1672) 1672
French (11) 11
German (3) 3
Norwegian (3) 3
Czech (2) 2
Hungarian (1) 1
Icelandic (1) 1
Portuguese (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 3, pp. 618 - 627.e3
Journal Article
1991, ISBN 9780919365087, xvii, 195
This report outlines some of the major elements that should be included in a comprehensive provincial strategy to prevent toxic pollution. The strategy should... 
Pollution | Hazardous wastes | Law and legislation | Environmental law
Book
Journal Article
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2014, Volume 12, Issue 9, pp. 1485 - e2
Background & Aims: Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through γ-chain-containing cytokines (interleukins 2, 4, 7, 9,... 
Tofacitinib | Crohn's disease | Randomized control trial | CP-690,550
Journal Article
Gastroenterology, ISSN 0016-5085, 10/2018, Volume 155, Issue 4, pp. 1045 - 1058
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2019, Volume 381, Issue 13, pp. 1201 - 1214
Patients with moderate-to-severe ulcerative colitis were randomly assigned to receive placebo or induction doses of ustekinumab. Patients who had a response to... 
Treatment outcome | Drug therapy | Analysis | Ulcerative colitis
Journal Article
Journal Article
CLINICAL PHARMACOKINETICS, ISSN 0312-5963, 12/2017, Volume 56, Issue 12, pp. 1513 - 1523
Certolizumab pegol is an effective biologic for patients with Crohn's disease (CD). Individual differences in certolizumab pegol apparent clearance (CL/F)... 
TRIAL | MODERATE | INFLAMMATORY-BOWEL-DISEASE | THERAPY | PROTEIN | EFFICACY | PHARMACOLOGY & PHARMACY | OUTCOMES | INFLIXIMAB | PRECISE 3 | Studies | Proteins | Antigens | Population | Tumor necrosis factor-TNF | Clinical medicine | Patients | Crohns disease
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 05/2006, Volume 4, Issue 5, pp. 621 - 630
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 07/2019, Volume 17, Issue 8, pp. 1525 - 1532.e1
Among immunosuppressive- and biologic-naïve patients with moderately-to-severely active Crohn’s disease (CD), a higher proportion of those treated with the... 
Mucosal Healing | SONIC | Corticosteroid-Free Clinical Remission | Serum Infliximab Concentrations | Exposure-Response | Mucosal Healing | ANTIBODIES | CROHNS-DISEASE | ADALIMUMAB | SERUM INFLIXIMAB | MAINTENANCE INFLIXIMAB | CERTOLIZUMAB PEGOL | INFLAMMATORY-BOWEL-DISEASE | IMMUNOMODULATORS | TROUGH | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 08/2016, Volume 375, Issue 8, p. e17.1
Journal Article
GASTROENTEROLOGY, ISSN 0016-5085, 10/2019, Volume 157, Issue 4, pp. 1007 - 1007
BACKGROUND & AIMS: Vedolizumab is a gut-selective monoclonal antibody for the treatment of moderately to severely active Crohn's disease (CD). We performed a... 
TRIALS | MULTICENTER | MANAGEMENT | INDUCTION | Monoclonal Antibody | Long-Term Outcome | MAGNETIC-RESONANCE ENTEROGRAPHY | alphabeta integrin | GHAS | INFLAMMATORY-BOWEL-DISEASE | THERAPY | CLINICAL EFFECTIVENESS | INDEX | MaRIA | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.